Senesco Technologies to Present at the 13th Annual BIO CEO & Investor Conference
February 09 2011 - 7:30AM
Business Wire
Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE
Amex: SNT) announced today that Leslie J. Browne, Ph.D., the
company’s President and Chief Executive Officer, will deliver a
corporate overview at the upcoming 13th Annual BIO CEO &
Investor Conference at the Waldorf Astoria in New York City.
Dr. Browne’s presentation will take place on Monday, February
14, 2011 at 1:30 p.m. on the 4th Floor.
A live webcast of the presentation will be available at
http://www.veracast.com/webcasts/bio/ceoinvestor2011/48109347.cfm.
Interested parties are encouraged to connect to the website at
least 15 minutes prior to the beginning of the presentation to
ensure a timely connection. A replay will also be accessible
through the aforementioned link for 90 days following the
event.
About Senesco Technologies, Inc.
Senesco Technologies is leveraging proprietary technology that
regulates programmed cell death, or apoptosis. Accelerating
apoptosis may have application in treating cancer, while delaying
apoptosis may have application in certain inflammatory and ischemic
diseases. The Company is preparing to initiate a human clinical
study in multiple myeloma with its lead therapeutic candidate,
SNS01-T. Senesco has partnered with leading-edge companies engaged
in agricultural biotechnology, and is entitled to earn research and
development milestones and royalties should its gene-regulating
platform technology is incorporated into its partners’
products.
Forward-Looking Statements
Certain statements included in this press release are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Actual results could
differ materially from such statements expressed or implied herein
as a result of a variety of factors, including, but not limited to:
the ability of the Company to consummate additional financings; the
development of the Company’s gene technology; the approval of the
Company’s patent applications; the successful implementation of the
Company’s research and development programs and collaborations; the
success of the Company's license agreements; the acceptance by the
market of the Company’s products; the success and timing of the
Company’s preliminary studies and preclinical research; competition
and the timing of projects and trends in future operating
performance; the Company’s ability to continue to comply with the
continued listing standards of the NYSE/AMEX; and other factors
expressed from time to time in the Company’s periodic filings with
the Securities and Exchange Commission (the "SEC"). As a result,
this press release should be read in conjunction with the Company’s
periodic filings with the SEC. The forward-looking statements
contained herein are made only as of the date of this press
release, and the Company undertakes no obligation to publicly
update such forward-looking statements to reflect subsequent events
or circumstances.
Senesco (AMEX:SNT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Senesco (AMEX:SNT)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Senesco Technologies (American Stock Exchange): 0 recent articles
More Senesco Technologies, Inc. News Articles